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Summary.-The concentration of5-fluorouracil (FU) in thoracic-duct lymph, portal-
veinblood andperipheral arterialbloodofbeagledogswasgreaterafteradministration
into the submucosa of the stomach than after the bolus i.v. injection. The concentra-
tion of FU in thoracic-duct lymph, portal-vein blood and arterial blood was least
following administration into the lumen of the stomach. The total FU recovered
over 6 h from thoracic-duct lymph was compared following the three routes of
administration and was found to be greatest following injection into the submucosa
of stomach.
5-FLUOROURACIL (FU) administered by
bolus i.v. injection is an established agent
in the palliation of disseminated gastro-
intestinal cancer, because of the relatively
high response rate (Ansfield and Curreri,
1959; Bireman and Vaitkevicus, 1960;
Field, 1963; Gold et al., 1959; Horton et al.,
1970; Jacobs, Luce and Wood, 1968).
FU has also been used as an adjuvant to
"curative" surgery by peroperative ad-
ministration into the lumen ofthe isolated
tumour-bearing segment of colon before
resection (Rousselot et al., 1968). It was
postulated that viable tumour cells in the
lumen of the gut would be destroyed, and
absorption of the drug into the systemic
circulation would destroy malignant cells
disseminated by surgical manipulation. An
8-year progress report (Rousselot et al.,
1972) describes noimprovementinsurvival
of those patients without involvement of
mesenteric nodes (American Cancer Soc-
iety, Stage I and II) but a significantly
improved survival among patients with
metastatic mesenteric nodes (Stage III).
No significant increase in morbidity or
mortality was associated with this tech-
nique.
It has been suggested (Khung et al.,
1966) that orally administered FU may
lead to a high concentration in the portal
system and be ofspecial benefit to patients
with hepatic metastases. Bateman et al.
(1971) randomized patients with dissemin-
ated adenocarcinoma to receive weekly FU
either orally or i.v. Clinically useful
response was found in 4000 of patients
receiving oral FU, compared with 21% of
patients receiving the drug i.v., but these
results were not statistically significant
because ofsmall sample size.
Yamada, Holyoke and Douglass (1976)
administered FU submucosally into the
colon of dogs, and demonstrated a higher
concentration in colonic wall, abdominal
lymph nodes and liver thanthatafterrapid
i.v. injection.
METHOD
The non-recovery experiments were per-
formed in 6 sex- and weight-matched beagle
dogs. Anaesthesia was induced with sodium
pentobarbitone and maintained after endo-
tracheal intubation with nitrous oxide and
halothane until the necessary cannulations
had been performed. Chloralose (100 mg/kg)
was then given by rapid i.v. bolus injection to
maintain anaesthesia during the 6h experi-
ments.
The thoracic duct was cannulated accord-
ing to the method ofWitte and Witte (1970).
The cannula was inserted for several inches
into the thoracic duct so that the tip of theM. THOMAS
cannula lay in the mid-thorax. The left
femoral artery was cannulated. The portal
vein was cannulated via one of its tributaries
and the tip of the catheter brought to lie at
the porta hepatis so that the tip was beyond
the last tributary of the portal vein. Both
ureters were cannulated.
The design of the experiment involved
collection of thoracic duct lymph over 6 h,
thereby preventing its return into the general
circulation and decreasing the true value of
concentration in portal-vein blood, arterial
blood and urine. This criticism was overcome
by pairing age- and weight-matched dogs for
each experiment. Only the thoracic duct was
cannulated in the first dog. In the second dog
of the pair the thoracic duct was left intact,
and the distribution ofdrug in the remainder
of the circulation was measured with greater
accuracy.
Because lymph production is criticially
affected by tissue perfusion, the arterial
blood pressure, central venous pressure, core
temperature andexpiredPCo2 weremonitored
throughout the 6h experiments, and adjust-
ments made to maintain homoeostasis. In
this way, thoracic-duct lymph flow was found
to be maintained at about the normal rate for
dogs (2 ml/kg/h) (Courtice, 1943; Watkins
and Fulton, 1938; Yoffey, 1932-3).
One mCi of [6-3H] FU (Radiochemical
Centre, Amersham; 10 mCi/ml, sp. act. 7-7
mCi/mg) was added to 13 mg/kg body wt of
unlabelled FU, mnaking a total volume for
injection of 3*5 ml per dog. Submucosal
injection was performed by gastrotomy and
injection of0-2 ml aliquots of this volume at
multiple sites.
The samples of lymph, portal-vein blood,
arterial blood and urine were collected at 10,
20, 30, 60, 90, ... 360 min, and immersed
immediately in an ice bath. The samples were
spun in a Beckman microfuge and 0-1ml of
lymph serum, blood serum and urine collected
for counting on an Intertechnique Multimat
scintillation spectrometer.
Initial experiments were performed to
determine the quenching effects of lymph,
blood and urine. The efficiency of counting
[6-3H]FU in the absence of biological
material was 52.4%. The efficiency of count-
ing standardized 3H-hexadecane (Radio-
chemical Centre, Amersham) was 50-7%.
Normal thoracic-duct lymph, portal-vein
blood, peripheral arterial blood and urine
were obtained from a dog which had never
been injected with any radioactive substance,
and the efficiency ofcounting was found to be
49%, 51.9%, 52-4% and 52-9% respectively.
The quenching effects of the biological fluids
were therefore considered to be negligible.
Further calculations were performed to
determinetheeffectofbackgroundirradiation,
and light activation on the specimens, and
these too were found to be negligible.
The solubilizer used for these experiments
wasNCS Tissue Solubilizer (Amersham/Searle
Corporation, Arlington Heights, Illinois). The
scintillation solution was a toluene mixture
containing 2,5-diphenyloxazole (PPO) (6 g/l)
and [1,4-di(2-(5-phenyloxazolyl))benzene]
(POPOP) (75mg/l).
RESULTS
The results (Figs. 1-3) show that
following the three methods ofadministra-
tion (submucosal, i.v. and intraluminal)
the concentration of FU in thoracic-duct
lymph, portal-vein blood, and arterial
blood is highest throughout the 6h
experiments after administration into the
submucosa ofthe stomach.
The total thoracic-duct lymph flow was
collected over the 6h experiments and it
was found that the recovery of 3H-FU was
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FIG. 2. Radioactive concentration in portal-veiin blood after administration of 1 *0 mCi
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FIG. 3.-Radioactive concentrationi in peripheral arterial blood after administration of 1- 0 mCi
3H-FU by submucosal (stomach), intravenous and iintraluminal (stomach) routes.
greatest after administration into the after i.v. administration than that follow-
submucosa of the stomach (Table, column ing submucosal (37%0) administration
a). (Table, Column b). Considered in the
The total urine output over the 6h context of the results presented in Figs. 1.
experiments was collected and the re- 2 and 3, it is likely that this finding
covery of 3H-FU was greater (48%) represents a "reservoir" action within the
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TABLE-(a) FU Recovered from Thoracic
Duct over 6 h Expressed as a % of Dose
Administered. (b) FU Recoveredfrom Urine
over 6 h Expressed as a % of Dose Ad-
ministered
(a) (b)
Submucosal (stomach) 1% 37%
Intravenous 0.7% 48%
Intraluminal (stomach) 02% 8-4%
submucosa of the stomach with "slow-
release" ofdrug into portal-vein blood and
thoracic-duct lymph.
DISCUSSION
It has been shown that, over 6 h, higher
concentrations of FU in thoracic-duct
lymph, portal-vein blood, and arterial
blood can be achieved after submucosal
injection into the stomach than after
rapid i.v. injection, or administration into
the lumen ofthe stomach.
Clinically, the submucosal injection
could be performed non-invasively via the
fibre-optic gastroscope. Otherwise, at the
time of operation, the FU could be
administered directly into the submucosa
of the stomach. It is known that
handling of tumours during resection
results in dissemination of malignant cells
into the blood stream and lymphatic
system. These surgically disseminated cells
from a gastric carcinoma might be rend-
ered nonviable by preoperative injection
ofFU into the gastric submucosa adjacent
to the tumour at fibre-optic gastroscopy.
Alternatively, the drug could be injected
peroperatively into the gastric submucosa
at sites to be included in the resection.
It has been shown that absorption of
soluble FU from the lumen ofthe stomach
is poor. It would seem unlikely, therefore,
that orally administered FU could be more
effective in the treatment of hepatic
metastases than i.v. injection of the same
dose of the drug, as has been suggested.
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